8-K 1 a17-10316_18k.htm 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 3, 2017

AMICUS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware |  | 001-33497 |  | 71-0869350
(State or other Jurisdiction of Incorporation) |  | (Commission File Number) |  | (IRS Employer Identification No.)

1 Cedar Brook Drive, Cranbury, NJ |  | 08512
(Address of Principal Executive Offices) |  | (Zip Code)

Registrant’s telephone number, including area code: (609) 662-2000

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On April 3, 2017, Amicus Therapeutics, Inc. (the “Company”) issued a press release announcing the completion of enrollment of the Company’s ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study. A copy of this press release is attached hereto as Exhibit 99.1.

The Company also provided a summary of its Epidermolysis Bullosa program of which a copy is attached hereto as Exhibit 99.2.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits: The Exhibit Index annexed hereto is incorporated herein by reference.

Exhibit No. |  | Description
99.1 |  | Press Release dated April 3, 2017 titled “Amicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study.”
99.2 |  | Presentation Materials — Epidermolysis Bullosa Program (April 2017)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| AMICUS THERAPEUTICS, INC.
Date: April 3, 2017 | By: | /s/ ELLEN S. ROSENBERG
| Name: | Ellen S. Rosenberg
| Title: | General Counsel and Corporate Secretary

3